Skip to content

Debt Repayments at other companies

Opko Health logo
Opko HealthOPK
$8.88M-7.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$60.09M
AMP
Amphastar PharmaceuticalsAMPH
$29K-23.7%
Organon logo
OrganonOGN
$32M-65.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$500M
Merck & Co. logo
Merck & Co.MRK
$1.14B-54.4%

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$824.68M+13.4%
Enterprise value$810.08M+12.7%
P/S-4.9×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s debt repayments?
Phathom Pharmaceuticals, Inc. (PHAT) reported debt repayments of $229.05M in Q1 2026.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.